CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
about
Epigenetic Alterations in Parathyroid CancersThe in vitro and vivo effects of nuclear and cytosolic parafibromin expression on the aggressive phenotypes of colorectal cancer cells: a search of potential gene therapy target.CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma.Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism.Understanding the genetic basis of parathyroid carcinoma.Clinicopathological correlates of hyperparathyroidism.Update on parathyroid carcinoma.Molecular genetics and epigenetics of nonfamilial (sporadic) parathyroid tumours.The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas.Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features.A nonfunctioning parathyroid carcinoma misdiagnosed as a follicular thyroid nodule.Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome.The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.Expression, function, and regulation of the embryonic transcription factor TBX1 in parathyroid tumors.A nationwide study on parathyroid carcinoma.
P2860
Q30398206-BB21E737-EFC4-4C32-AD5C-07600406310DQ33618790-1F6E542A-EF52-4AEF-8ADC-BE78C9CDB5A5Q34396517-29BEC74D-06A6-4F55-BB83-CA1ECE15BECFQ36680526-BBA32137-8F00-4FEC-BEE3-01687EBB43EBQ37378253-CE2DFC14-4A48-4B1F-8665-397CF7E1A41CQ38176824-7D34F45D-9741-4141-8EE4-8B437E2F94A9Q38545172-3291120C-95C2-4B34-B4E1-1FB30FB4C641Q38784218-875464FA-B6DB-4E38-A24A-10889FAC3D2CQ38806483-72E1439A-59A9-4DCE-8756-E32EEA19D8A1Q38858757-6E5DC8D7-D70C-4144-926E-DC7B54A1258FQ42695925-8AD70820-5F50-40A5-BE7F-19727BA534E7Q43157359-E59FE373-D4A4-43D6-BCF1-495D2B9174DFQ44004244-4A210A13-11FC-4F7A-8FC8-4146E5791D48Q45879500-2DBB4A49-2BC7-4638-8AB0-C67E22D0011AQ45907440-330E48C0-B1D4-4F2E-9F5A-61FBD6FD94DBQ47664476-E4EF2C44-BC96-4C6F-A5A5-1218B6B9E331Q52778896-28823960-AB80-4118-A4BD-6670CD95AC43
P2860
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
@en
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
@nl
type
label
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
@en
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
@nl
prefLabel
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
@en
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
@nl
P2093
P2860
P50
P356
P1476
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer
@en
P2093
Chiara Banti
Claudio Marcocci
Edda Vignali
Elena Pardi
Federica Saponaro
Filomena Cetani
Guido Gasparri
Liborio Torregrossa
Maria Rosa Pelizzo
Massimo Rugge
P2860
P304
P356
10.1530/EC-13-0046
P577
2013-10-28T00:00:00Z